Genentech, Inc.
NEWS
Genentech announced on Wednesday that it has seen positive topline results from Archway, its Phase III study looking into its Port Delivery System (PDS) with ranibizumab for the treatment of neovascular or “wet” age-related macular degeneration.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 27, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 20, 2020.
The approval was based on interim analysis from the company’s Phase III IMpower110 trial.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 18, 2020.
Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look.
Genentech, a Roche company, announced positive results from the Phase II CITYSCAPE clinical trial in PD-L1-positive metastatic non-small cell lung cancer.
Pharma veteran Michael Varney, Genentech’s head of Research and Development, will retire from the company at the end of July after spending 15 years with the company.
Genentech, a Roche company, presented one-year data from FIREFISH Part 2, its pivotal trial of risdiplam in infants one to seven months old with symptomatic Type 1 spinal muscular atrophy.
JOBS
IN THE PRESS